Dana-Farber Cancer Institute, Boston, MA, USA.
Semin Oncol. 2011 Oct;38(5):635-47. doi: 10.1053/j.seminoncol.2011.04.014.
Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Administration (FDA)-approved indication for any of the HGFs. Erythropoiesis-stimulating agents (ESAs: epoetin alfa, darbepoetin alfa), myeloid growth factors (MGFs: filgrastim, pegfilgrastim, sargramostim), and the newest group of HGFs, thrombopoiesis-stimulating agents (TSAs: romiplostim, eltrombopag), can increase peripheral blood counts in some patients, and may ameliorate some of the signs and symptoms of MDS-associated bone marrow failure. Although HGFs are generally considered "supportive care" measures, recent data suggest that HGFs may alter the natural history of disease in MDS, either for better or worse. This review examines data on the safety and effectiveness of HGFs for patients with MDS.
造血生长因子 (HGFs) 仍然是骨髓增生异常综合征 (MDS) 患者最广泛使用的药物类别，尽管 MDS 的疾病修正治疗方法（如阿扎胞苷、地西他滨和来那度胺）已经出现，并且目前没有任何 HGF 被美国食品和药物管理局 (FDA) 批准用于 MDS 的特定适应症。红细胞生成刺激剂 (ESAs：epoetin alfa、darbepoetin alfa)、粒细胞集落刺激因子 (MGFs：filgrastim、pegfilgrastim、sargramostim) 和最新的一组 HGFs，血小板生成刺激剂 (TSAs：romiplostim、eltrombopag)，可增加一些患者的外周血计数，并可能改善 MDS 相关骨髓衰竭的一些体征和症状。虽然 HGFs 通常被认为是“支持性护理”措施，但最近的数据表明，HGFs 可能会改变 MDS 的疾病自然史，无论是好是坏。这篇综述检查了 HGFs 治疗 MDS 患者的安全性和有效性数据。
